Antibodies against vascular endothelial growth factor improve early renal dysfunction in experimental diabetes

Journal of the American Society of Nephrology

Volumn 12, Issue 5, 2001, Pages 993-1000

  De Vriese, A S ^a   Tilton, R G ^a   Elger, M ^a   Stephan, C C ^a   Kriz, W ^a   Lameire, N H ^a  

^a GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; MONOCLONAL ANTIBODY; NITRIC OXIDE SYNTHASE; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD VESSEL PERMEABILITY; CAPILLARY ENDOTHELIUM; CELL TYPE; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC NEPHROPATHY; EPITHELIUM CELL; FEMALE; GLOMERULUS FILTRATION RATE; HYPERGLYCEMIA; KIDNEY EPITHELIUM; KIDNEY HYPERTROPHY; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEINURIA; RAT; STREPTOZOCIN DIABETES; ULTRAFILTRATION;

EID: 0035034655     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Diabetic kidney disease: The role of growth factors
2. Hyperglycemia and diabetic kidney disease. The case for transforming growth factor-beta as a key mediator
3. Role of vascular endothelial growth factor in the regulation of angiogenesis
4. Nitric oxide synthase lies downstream from vascular endothelial growth factor-induced but not basic fibroblast growth factor-induced angiogenesis
5. Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF
6. VEGF upregulates ecNOS message, protein, and NO production in human endothelial cells
7. Vascular permeability factor mRNA and protein expression in human kidney
8. Expression of vascular endothelial growth factor and its receptors in human renal ontogenesis and in adult kidney
9. 125I]VEGF binding sites
10. VEGF/VPF: A modulator of microvascular function with potential roles in glomerular pathophysiology
11. Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes
12. Suppression of transforming growth factor beta and vascular endothelial growth factor in diabetic nephropathy in rats by a novel advanced glycation end product inhibitor, OPB-9195
13. Vascular dysfunction induced by elevated glucose levels in rats is mediated by vascular endothelial growth factor
14. Determination of glomerular filtration rate in rats
15. Glucose-induced protein kinase C activation regulates vascular permeability factor mRNA expression and peptide production by human vascular smooth muscle cells in vitro
16. Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells
17. Increased expression of TGF-β1, VEGF, and fibronectin in rat glomerular endothelial cells by high ambient glucose
18. Vascular endothelial growth factor and vascular permeability changes in human diabetic retinopathy
19. Vascular endothelial growth factor and its receptors in control and diabetic rat eyes
20. VEGF(165) mediates glomerular endothelial repair
21. Longterm prevention of renal insufficiency, excess matrix gene expression, and glomerular mesangial matrix expansion by treatment with monoclonal antitransforming growth factor-beta antibody in db/db diabetic mice
22. Therapy with antisense TGF-beta1 oligodeoxynucleotides reduces kidney weight and matrix mRNAs in diabetic mice
23. Inhibitory effect of a growth hormone receptor antagonist (G120K-PEG) on renal enlargement, glomerular hypertrophy and urinary albumin excretion in experimental diabetes in mice
24. Growth hormone receptor antagonism prevents early renal dysfunction in nonobese diabetic mice
25. Vascular endothelial growth factor and diabetes. The agonist versus antagonist paradox
26. Nitric oxide synthase isoforms and glomerular hyperfiltration in early diabetic nephropathy
27. Role of endothelium-derived nitric oxide in the pathogenesis of the renal hemodynamic changes of experimental diabetes
28. Renal effects of acute and chronic nitric oxide inhibition in experimental diabetes
29. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy
30. Vascular endothelial growth factor induces endothelial fenestrations in vitro
31. Role of nitric oxide in renal hemodynamics
32. The impact of experimental diabetes mellitus in rats on glomerular capillary number and sizes
33. Advanced glycation end products increase retinal vascular endothelial growth factor expression
34. Interaction of angiotensin II and mechanical stretch on vascular endothelial growth factor production by human mesangial cells
35. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo
36. Vascular endothelial growth factor is induced in response to transforming growth factor-β in fibroblastic and epithelial cells
37. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I
38. Glomerular endothelial cells in culture express and secrete vascular endothelial growth factor
39. Amelioration of vascular dysfunctions in diabetic rats by an oral PKCβ inhibitor
40. Prevention of glomerular dysfunction in diabetic rats by treatment with d-α-tocopherol
41. Dual regulation of vascular endothelial growth factor bioavailability by genetic and proteolytic mechanisms
42. Pathogenesis of diabetic vascular disease: Evidence for the role of reduced heparan sulphate proteoglycan